sorafenib + tanespimycin

Sorafenib + tanespimycin is a combination drug regimen investigated primarily for cancer treatment, including renal cancer, melanoma, and colorectal cancer. Sorafenib is a multi-kinase inhibitor targeting Raf kinase among others, which inhibits tumor cell proliferation and angiogenesis. Tanespimycin (also known as 17-AAG) is an inhibitor of heat shock protein 90 (Hsp90), which affects the Raf kinase signaling pathway by destabilizing client proteins involved in tumor growth. The combination aims to enhance antitumor effects by simultaneously inhibiting Raf kinase signaling with sorafenib and disrupting Hsp90 function with tanespimycin. Clinical studies have shown that this combination can be administered safely at recommended phase II doses of 400 mg oral sorafenib twice daily plus 400 mg/m² intravenous tanespimycin on days 1, 8, and 15 every 28 days. Pharmacodynamic effects include decreased Hsp90 levels and induction of Hsp70. Clinical efficacy was observed notably in kidney cancer and melanoma patients during phase I trials.

Other names

17-AAG and sorafenib